Companies · Pharmaceuticals

Viking Scientific, Inc.

SAN MARCOS · Pharmaceuticals

Diligence memoA one-page analyst read on Viking Scientific, Inc. — recommendation, valuation, rhythm, risks.
$114K
Total raised · real
1
Rounds
Latest step-up
Top 100%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Viking Scientific, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.36× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.8 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Viking Scientific, Inc. is one of 1610 Pharmaceuticals companies tracked from SAN MARCOS. By capital raised it ranks in the long tail (ahead of 1% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 504
Reg D exemption
7
Investors (latest)
2020-09-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3M$2.5M$3.8M$5.0MPre-Seed · 2020-09-15 Raised $114K (real) Modeled valuation $4.7M (est)$114K$4.7MPre-Seed2020

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$114K · 2020

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$4.7M
Base estimate est.
$64K
Conservative case
$50.5M
Upside case
$631K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
5.8 yr
Elapsed time used
5.8 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
5.8 yr
On record since
2020
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$114K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.3× of median
This company$114K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$4.7M
Sector median$76.1M

Raised more than 1% of sector peers (real $). Modeled value above 9% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #41 of 46.

This companyCohort peer
$1.0M$10.0M$100.0M$10K$100K$1.0M$10.0MCapital raised (log)Elion Oncology, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Cyclone Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Sonnet Biotherapeutics, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Fastball Capital Group, Llc · Pre-Seed Raised $750K · modeled $35.5M (est)TamRx, LLC · Pre-Seed Raised $700K · modeled $33.1M (est)Veana Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $32.8M (est)Ariz Precision Medicine, Inc. · Pre-Seed Raised $685K · modeled $32.4M (est)Vascarta Inc. · Pre-Seed Raised $649K · modeled $28.1M (est)Enfuego Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $27.0M (est)Sincerus Pharmaceuticals Inc · Pre-Seed Raised $506K · modeled $23.9M (est)Neurodon Corp · Pre-Seed Raised $500K · modeled $23.7M (est)Elite Pharmaceuticals Inc /Nv/ · Pre-Seed Raised $3.3M · modeled $23.4M (est)Viking Scientific, Inc. (this company) Raised $114K · modeled $4.7M (est)Viking Scientific, Inc.
CompanyStageRaised · realValue · estvs peer med.
Elion Oncology, Inc.Pre-Seed$1.0M$47.3M3.55×
Cyclone Therapeutics, Inc.Pre-Seed$800K$37.8M2.84×
Sonnet Biotherapeutics, Inc.Pre-Seed$750K$35.5M2.66×
Fastball Capital Group, LlcPre-Seed$750K$35.5M2.66×
TamRx, LLCPre-Seed$700K$33.1M2.48×
Veana Therapeutics, Inc.Pre-Seed$1.4M$32.8M2.46×
Ariz Precision Medicine, Inc.Pre-Seed$685K$32.4M2.43×
Vascarta Inc.Pre-Seed$649K$28.1M2.10×
Enfuego Therapeutics, Inc.Pre-Seed$1.0M$27.0M2.02×
Sincerus Pharmaceuticals IncPre-Seed$506K$23.9M1.79×
Neurodon CorpPre-Seed$500K$23.7M1.77×
Elite Pharmaceuticals Inc /Nv/Pre-Seed$3.3M$23.4M1.75×
Viking Scientific, Inc. this companyPre-Seed$114K$4.7M0.36×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$114K2020-09-15$631K$4.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$114K2020-09-15
    • First recorded raise — entered as Pre-Seed.
    • 7 investors on this round.
Intelligence
Modeled next raise
$182K
Modeled next size est.range $118K$291K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Paul Fisher3 other2020-09
Frank J. Papatheofanis2020-09
Glenn J. Mattes2020-09
Gregory Fisher2020-09
Jeffrey J. Patton2020-09
Joe J. DePinto2020-09
John Dempsey2020-09
Registry & provenance

Viking Scientific, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1724333
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
PSG of Sarasota, LLCPharmaceuticalsPre-Seed$114K$5.4Msame sector · same stage
Return Health Inc.PharmaceuticalsPre-Seed$115K$3.1Msame sector · same stage
ALVP Holdings, LLCPharmaceuticalsPre-Seed$117K$5.5Msame sector · same stage
Olfax, LlcPharmaceuticalsPre-Seed$110K$524Ksame sector · same stage
Presa Solutions IncPharmaceuticalsPre-Seed$110K$1.1Msame sector · same stage
HealthScripts of America - Lubbock, LLCPharmaceuticalsPre-Seed$120K$5.7Msame sector · same stage
HealthScripts of America - Portland, LLCPharmaceuticalsPre-Seed$105K$5.0Msame sector · same stage
Uppi, LlcPharmaceuticalsPre-Seed$105K$5.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Viking Therapeutics, Inc.BiotechnologySeed$162.3M92%
Marius Pharmaceuticals, LLCPharmaceuticalsSeries B$129.3M83%
Aarvik Therapeutics, Inc.PharmaceuticalsSeries A$5.1M82%
Alto Labs LLCPharmaceuticalsPre-Seed$703K81%
Titan Pharmaceuticals IncPharmaceuticalsSeries A$23.0M81%
Hapten Sciences, Inc.PharmaceuticalsSeed$64.1M81%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B81%
LSK BioPartners, Inc.PharmaceuticalsSeries B$680.1M80%
Frequently asked
How much funding has Viking Scientific, Inc. raised?
Viking Scientific, Inc. has raised approximately $114K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Viking Scientific, Inc.'s estimated valuation?
Provath's modeled valuation for Viking Scientific, Inc. is approximately $4.7M (modeled range $64K–$50.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Viking Scientific, Inc. at?
Viking Scientific, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Sep 15.
What does Viking Scientific, Inc. do and where is it based?
Viking Scientific, Inc. operates in the Pharmaceuticals sector, based in SAN MARCOS.
Explore related

See where Viking Scientific, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Viking Scientific, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.